Using SCIEX QTRAP® LC-MS/MS Systems and technology
An LC-MS/MS method for the analysis of 6 designer drugs was developed utilizing a designer drug library for high confidence identification either by at least two MRM transitions per compound or by performing an information dependent acquisition to generate MS/MS spectra using the linear ion trap of the QTRAP System. The obtained MS/MS spectra can be searched against spectral libraries using the Analyst Reporter Software for unambitious identification and confirmation.
Recently, trends have been seen within the drugs of abuse arenas to suggest that attempts are being made to bypass controlled substance laws, with novel compounds appearing on the market that are similar in structure to current drugs of abuse. These “designer drugs” or “legal highs” have caused concern due to their unknown quantity in terms of potency, side effects, health consequences and potential for abuse. As the number of new designer drugs is constantly rising, methods which can be easily expanded and have a non-selective sample preparation are needed.
The method presented here uses a simple dilute and shoot sample preparation and using a Scheduled MRM™ Algorithm on a QTRAP System to quantify and identify a number of these compounds in urine, specifically ketamine, norketamine, dehydronorketamine, 3-methoxyeticyclidine (3-MeO-PCE), 3-methoxyphencyclidine (3-MeO-PCP) and methoxetamine.
To increase the reliability of identification by acquiring automatic triggering of MS/MS spectra and spectral library comparison, a second method was established utilizing QTRAP System technology. For this approach an information dependent acquisition (IDA) method was set up with one MRM transition per compound for detection and on-the-fly acquisition of EPI scans to obtain highly sensitive MS/MS spectra of the analytes for identification.
Sample preparation: A simple dilution process has been chosen as sample preparation to enable a fast procedure without applying any selective extraction procedure:
HPLC conditions: LC separation was achieved on an Agilent 1290 HPLC system by applying an 8 minute gradient on a Phenomenex Kinetex C18 100Å, 150 x 3 mm with KrudKatcher ULTRA HPLC In-Line Filter, 0.5 μm. Mobile phase A was water with formic acid and ammonium formate and mobile phase B was acetonitrile. The injection volume was 10 μL.
Mass spectrometry conditions: A SCIEX QTRAP LC-MS/MS System equipped with a Turbo V™ Ion Source was used. Source and gas parameters were optimized for best performance, and individual compound parameters were optimized using infusion. At least 2 MRM transitions per compound were optimized. The Scheduled MRM™ Algorithm parameters used were a target scan time of 0.3 sec and a MRM detection window of 40 sec.
For the IDA method, a target scan time of 0.1 sec was used. The EPI spectra for identification were acquired using dynamic fill time and collision energy spread to obtain detailed spectral information.
Using this method, it was possible to analyze the compounds ketamine, norketamine, dehydronorketamine, 3-methoxyeti-cyclidine, 3-methoxyphencyclidine and methoxetamine in a single method with an injection to injection time of 8 minutes (Figure 1). The method was found to be very specific as no interfering signals were observed in blank urine samples.
Quantitative performance has been demonstrated and shows accuracies within 15% of nominal at the LOQ and %CV of 15%, also at the LOQ and within 10% for the higher concentrations. However, for dehydronorketamine the performance was slightly lower with accuracies around 20% of nominal at the LOQ and %CV of 20%, also at the LOQ and within 15% for the higher concentrations.
An LOQ of 1 ng/mL after 1:50 dilution of the urine samples was estimated and additionally confirmed by signal to noise calculations (Figure 2). Excellent linearity was obtained for all analytes in the applied concentration range of 1 to 200 ng/mL with an applied weighting factor of 1/x2 (Figure 3).
All analytes were infused post column using a tee connector during injection of solvent A and a blank urine sample, which was diluted 1:50 and 1:10 respectively. Figure 4 clearly shows the benefit of a high dilution factor for urine analysis as this causes a significant decrease of ion suppression. At a dilution factor of 50, no ion suppression could be observed compared to the solvent injection and the injection of 1:10 diluted urine at relevant retention times.
To increase confidence in identification full scan MS/MS experiments using the linear ion trap of the QTRAP System can be performed and acquired spectra can be searched against mass spectral libraries (Figure 5). With this approach there is no need to monitor a second MRM transition as a qualifier for identification.
An LC-MS/MS method for the analysis of 6 designer drugs was developed utilizing a designer drug library for high confidence identification either by at least two MRM transitions per compound or by performing an information dependent acquisition to generate MS/MS spectra using the linear ion trap of the QTRAP System. The obtained MS/MS spectra can be searched against spectral libraries using the Analyst Reporter Software for unambitious identification and confirmation.
The use of the Scheduled MRM Algorithm allows inclusion of further analytes and internal standards without sacrificing cycle time and therefore data points across the chromatographic peaks.
The very simple, fast and non-selective dilution step shows to be a reliable and robust sample preparation and ensures that no analytes are lost which can be the case if a selective extraction procedure is performed instead.